$2.38 Earnings Per Share Expected for Clorox Co (NYSE:CLX) This Quarter

Share on StockTwits

Wall Street analysts predict that Clorox Co (NYSE:CLX) will report $2.38 earnings per share for the current quarter, Zacks reports. Three analysts have provided estimates for Clorox’s earnings, with the highest EPS estimate coming in at $2.59 and the lowest estimate coming in at $2.06. Clorox reported earnings per share of $1.59 in the same quarter last year, which would suggest a positive year over year growth rate of 49.7%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Monday, November 2nd.

On average, analysts expect that Clorox will report full year earnings of $7.73 per share for the current year, with EPS estimates ranging from $7.40 to $7.90. For the next financial year, analysts forecast that the business will report earnings of $8.06 per share, with EPS estimates ranging from $7.60 to $8.89. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Clorox.

Clorox (NYSE:CLX) last released its quarterly earnings data on Monday, August 3rd. The company reported $2.41 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.41. Clorox had a net margin of 13.97% and a return on equity of 138.70%. The business had revenue of $1.98 billion during the quarter, compared to analysts’ expectations of $1.86 billion. During the same quarter in the prior year, the company earned $1.88 EPS. The firm’s quarterly revenue was up 21.9% on a year-over-year basis.

A number of analysts recently commented on CLX shares. Citigroup upped their price objective on shares of Clorox from $206.00 to $246.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. DA Davidson lowered their price objective on shares of Clorox from $269.00 to $263.00 and set a “buy” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Clorox from $203.00 to $235.00 and gave the company an “overweight” rating in a research report on Thursday, July 16th. Credit Suisse Group increased their target price on Clorox from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Zacks Investment Research cut Clorox from a “buy” rating to a “hold” rating and set a $249.00 target price for the company. in a report on Thursday, August 6th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. Clorox presently has an average rating of “Hold” and a consensus target price of $206.54.

In other news, SVP Andrew J. Mowery sold 12,932 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $235.97, for a total transaction of $3,051,564.04. Following the completion of the transaction, the senior vice president now directly owns 18,456 shares in the company, valued at approximately $4,355,062.32. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Diego J. Barral sold 10,041 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $235.59, for a total transaction of $2,365,559.19. Following the transaction, the senior vice president now owns 13,931 shares of the company’s stock, valued at $3,282,004.29. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Several institutional investors have recently bought and sold shares of CLX. Costello Asset Management INC acquired a new stake in Clorox in the 2nd quarter valued at about $27,000. Fred Alger Management LLC acquired a new stake in Clorox in the 1st quarter valued at about $28,000. RPG Investment Advisory LLC lifted its stake in Clorox by 98.5% in the 2nd quarter. RPG Investment Advisory LLC now owns 129 shares of the company’s stock valued at $28,000 after purchasing an additional 64 shares during the last quarter. Rosenberg Matthew Hamilton acquired a new stake in Clorox in the 2nd quarter valued at about $29,000. Finally, Knuff & Co LLC lifted its stake in Clorox by 174.0% in the 2nd quarter. Knuff & Co LLC now owns 137 shares of the company’s stock valued at $30,000 after purchasing an additional 87 shares during the last quarter. Institutional investors own 79.18% of the company’s stock.

Shares of CLX traded down $2.43 during trading hours on Monday, reaching $209.22. The stock had a trading volume of 1,311,353 shares, compared to its average volume of 1,379,446. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 3.06. Clorox has a 52 week low of $144.31 and a 52 week high of $239.87. The firm has a 50-day moving average of $216.80 and a 200 day moving average of $208.16. The company has a market cap of $26.36 billion, a P/E ratio of 28.47, a P/E/G ratio of 3.85 and a beta of 0.27.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 20th. Stockholders of record on Wednesday, November 4th will be paid a dividend of $1.11 per share. The ex-dividend date is Tuesday, November 3rd. This represents a $4.44 dividend on an annualized basis and a dividend yield of 2.12%. Clorox’s dividend payout ratio is 60.33%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Read More: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply